ClinicalTrials.gg
CompletedNCT02650817Updated Aug 18, 2022

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

A Phase 1 interventional study of RAD1901 in Metastatic Breast Cancer, sponsored by Stemline Therapeutics, Inc.. Completed at 5 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-18.

Sponsored by Stemline Therapeutics, Inc. (part of Menarini Group) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2018, 8 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing elacestrant in Breast Neoplasms — 15 open to participants now, 18 under way, 3 of them phase 3. elacestrant · Breast Neoplasms.

Enrollment
22nd of 24
16 · median 72
Started
2016
the only one that year
Phase 1
4 of 24
none open now
Registered
2nd of 24
by date
Lead sponsor
9 of 24
Stemline Therapeutics, Inc.

Among the 24 studies testing elacestrant in Breast Neoplasms, this one is the 22nd largest by enrollment, is the only one that started in 2016, is one of 4 in phase 1, and was the 2nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 24 studies testing elacestrant in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About elacestrant

elacestrant: first FDA approval 2023 (ORSERDU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing elacestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to visualize and quantify ER-binding sites during treatment with Elacestrant (RAD1901)

Read the detailed description

The purpose of this study is to visualize and quantify ER-binding sites during treatment with Elacestrant (RAD1901) using 16α-18F-Fluoro-17β-estradiol (FES) positron emission tomography (PET) imaging

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Patients with -proven, ER-positive, human epidermal growth factor receptor 2 ()-negative, locally advanced, inoperative, and/or mBC
  2. Tumor progression after ≥ 6 months of at least 1 line of hormonal systemic treatment (SERM, SERD, or aromatase inhibitor) in the setting
  3. according to (RECIST) criteria v1.1 or clinically evaluable disease
  4. Greater than or equal to 18 years of age
  5. Patients must be
  6. >3 months

Key Exclusion Criteria:

  1. Greater than 3 lines of endocrine therapy for metastatic disease.
  2. Prior anti-cancer treatment or drug therapy within the following windows:

    1. Tamoxifen or fulvestrant therapy \< 42 days before 1st 18FES-PET scan
    2. Any other anti-cancer endocrine therapy \< 14 days before 1st dose of study drug
    3. Any chemotherapy \< 28 days before 1st dose of study drug
    4. Any investigational drug therapy \< 28 days or 3 half-lives (whichever is longer) prior to the 1st dose of study drug 2. Patients with untreated or symptomatic central nervous system (brain) metastases 3. Patients with known endometrial disorders, including evidence of endometrial hyperplasia, dysfunctional uterine bleeding, or cysts
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Elacestrant (formerly RAD1901)

    To receive daily oral elacestrant

    Drug: RAD1901

Interventions

  • RAD1901, a novel selective ER degrader (SERD)

    Also known as: Elacestrant

06

What researchers measure

Primary outcomes

  1. Effect of ER Binding after RAD1901 treatment

    To determine the effect of RAD1901 treatment on the estrogen receptor (ER) expression and estradiol binding to the ER in lesions from patients with metastatic breast cancer (mBC)

    Time frame: 14 Days after the first dose

Secondary outcomes

  1. Correlation of FES uptake after RAD1901 treatment to clinical response

    To determine if any changes in ER binding, as observed through FES uptake, correlate with clinical response

    Time frame: Every 8 weeks for to up 12 months of treatment

  2. Tumor response will be evaluated in patients with measurable or evaluable disease, using RECISTv1.1 guidelines

    To determine if there is a tumor response to RAD1901 treatment

    Time frame: Every 8 weeks for to up 12 months of treatment

  3. Safety and Tolerability assessed in terms of adverse events, serious adverse events, ECG, physical examination, ECOG performance status, vital signs, and laboratory values

    Characterization of the safety of RAD1901 in this patient population

    Time frame: Up to 30 days after the end of treatment

  4. Plasma concentrations of RAD1901 will be assessed at predefined intervals

    Pharmacokinetic data will be collected.

    Time frame: Every 28 days for up to 3 cycles

07

Study locations

5 sites
  • Institut Jules Bordet
    Bruxelles, 1000, Belgium
  • UZ Leuven Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Vrije Universiteit Medisch Centrum (VUMC)
    Amsterdam, Netherlands
  • Universitair Medisch Centrum Groningen (UMCG)
    Groningen, Netherlands
  • Erasmus Medical Center
    Rotterdam, Netherlands
08

References and documents

Publications

  • Jager A, de Vries EGE, der Houven van Oordt CWM, Neven P, Venema CM, Glaudemans AWJM, Wang Y, Bagley RG, Conlan MG, Aftimos P. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging. Breast Cancer Res. 2020 Sep 11;22(1):97. doi: 10.1186/s13058-020-01333-3. PubMed 32912274 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Aug 2018, 28 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 28 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2016
First posted
Jan 8, 2016
StartActual
Apr 1, 2016
Primary completionActual
Aug 30, 2018
CompletionActual
Oct 18, 2019
Last update
Aug 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02650817
Responsible party
Sponsor
First posted
Jan 8, 2016
Start date
Apr 1, 2016
Primary completion
Aug 30, 2018
Completion
Oct 18, 2019
Last update
Aug 18, 2022

Study contacts

Elisabeth GE de Vries, MD
principal investigator · Universitair Medisch Centrum Groningen (UMCG)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elacestrant

Start the discussion